Edesa Biotech (EDSA) has released an update.
Edesa Biotech’s CEO and Founder, Par Nijhawan, has made a strategic investment of up to $5 million in the company, demonstrating strong confidence in its future growth prospects. This move includes an immediate $1.5 million investment through the purchase of Series A-1 Convertible Preferred Shares and warrants. The investment aims to support Edesa’s development pipeline in treating inflammatory and immune-related diseases.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
